Vardenafil Tablet, Orally Disintegrating
Product Images NDC 62332-235

10 FDA label images from Alembic Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Vardenafil (NDC 62332-235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Vardenafil Fig1)

Figure 1 (Vardenafil Fig1)
This figure contains three line graphs displaying mean maximal changes for systolic blood pressure (mmHg), diastolic blood pressure (mmHg), and heart rate (bpm) over time intervals (24h, 8h, 4h, 1h) prior to Vardenafil treatment before NTG administration. Each graph shows trend lines with error bars for variability.*
FDA Label Image

Figure 2 (Vardenafil Fig2)

Figure 2 (Vardenafil Fig2)
A line chart depicting the mean change in blood pressure (mmHg) over time (hours) for placebo and vardenafil 5 mg administered either simultaneously or with a 6-hour separation. The chart includes distinct lines with different markers for each condition, illustrating the variation of effects during a 6-hour period.*
FDA Label Image

Figure 3 (Vardenafil Fig3)

Figure 3 (Vardenafil Fig3)
A line graph depicting mean change in blood pressure (mmHg) over time (hours) for placebo and vardenafil 5 mg under different conditions. Four lines represent placebo simultaneous and 6-hour separation, and vardenafil simultaneous and 6-hour separation, illustrating the time-dependent drug effects compared to placebo.*
FDA Label Image

Figure 4 (Vardenafil Fig4)

Figure 4 (Vardenafil Fig4)
A line graph depicting the mean change in a variable (mmHg) over time (hours) for placebo and Vardenafil at 10 mg and 20 mg doses across two stages. The x-axis represents time in hours from 0 to 6, and the y-axis shows mean change in mmHg, ranging from -10 to 5.*
FDA Label Image

Figure 5 (Vardenafil Fig5)

Figure 5 (Vardenafil Fig5)
Line graph depicting the mean change in mmHg over time (hours) for Vardenafil 5 mg, Vardenafil 10 mg, and placebo groups in two stages. The x-axis represents time in hours up to 6 hours, and the y-axis shows mean change in mmHg ranging from -10 to 10.*
FDA Label Image

Figure 6 (Vardenafil Fig6)

Figure 6 (Vardenafil Fig6)
A line graph titled Terazosin displaying mean change in mmHg over time (hours) up to 6 hours. The graph compares placebo and vardenafil at 10 mg and 20 mg doses, with separate lines for 6-hour separation and simultaneous administration. Data points show variations in blood pressure changes for each treatment group over the time course.*
FDA Label Image

Figure 7 (Vardenafil Fig7)

Figure 7 (Vardenafil Fig7)
A line graph titled "TAMSULOSIN" displaying mean change in mmHg on the y-axis over a 6-hour time period on the x-axis. The graph compares mean changes for placebo and vardenafil (10 mg and 20 mg) taken either with 6-hour separation or simultaneously, showing multiple lines with different markers for each condition.*
FDA Label Image

Figure 8 (Vardenafil Fig8)

Figure 8 (Vardenafil Fig8)
A pharmacokinetic line graph showing plasma concentration (µg/L) of Vardenafil over time (hours) after dosing. The curve indicates a rapid rise to peak concentration within the first 1-2 hours, followed by a gradual decline to near baseline levels by 15 hours. Vertical error bars represent variability in plasma concentrations at each time point.*
FDA Label Image

Vardenafil HCl Odt mg 10

Vardenafil HCl Odt mg 10
Vardenafil Hydrochloride Orally Disintegrating Tablets, 10 mg per tablet, in a printed carton label for oral use. The package contains 4 tablets and is labeled Rx only. The labeler is Alembic Pharmaceuticals Inc. The design includes instructions to place the tablet on the tongue for oral disintegration, with dosage strength and NDC 62332-235-04 displayed clearly.*
FDA Label Image

Structure (Vardenafil Str)

Structure (Vardenafil Str)
Chemical structure of Vardenafil hydrochloride trihydrate, depicting its molecular configuration including the core heterocyclic rings and various functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.